ClinicalTrials.gg
DrugRead study by study

Capivasertib clinical trials

Also written AZD5363 and Truqap.

studies test it
55
open now
15
in phase 3
10
first study started
2010
ClinicalTrials.gov finds 68 studies for capivasertib. How that becomes 55 here

Every study that search finds has been read, to see whether and how it gives capivasertib. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count

  1. 68Found by its intervention search · See all 68 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 46 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. −1
    Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
  3. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  4. 68Give capivasertib to participants
  5. −2Observe patients on it, or give it outside a trial
  6. −2Compare another treatment with it
  7. −9Give it beside what is tested
  8. 55Test it: the count on this site

Get an email when these change. Save the capivasertib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Nov 2023 · TRUQAP · NDA 218197 (FDA, Drugs@FDA)
European Union
17 Jun 2024 · Truqap · EMEA/H/C/006017 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Capivasertib
34

Brand

Truqap
7

Development codes

AZD5363
32

Studies by the year they started

54 studies that test it; most in 2014 (9); 1 more planned to start later

Studies that test capivasertib, by start year
YearStudies
20101
20111
20131
20149
20156
20163
20171
20184
20193
20202
20217
20222
20231
20243
20254
20266

By phase

A phase 1/2 study counts in both.

Phase 1
24
Phase 2
29
Phase 3
10

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 21 · Other 34

AstraZeneca (21) · National Cancer Institute (NCI) (3) · UNICANCER (2) · Samsung Medical Center (2) · VA Office of Research and Development (2) · Institute of Cancer Research, United Kingdom (2) · M.D. Anderson Cancer Center (1) · Velindre NHS Trust (1)

Often tested with

Tested in the same studies.

Durvalumab (6) · Olaparib (5) · Vistusertib (5) · AZD4547 (4) · Ceralasertib (4) · Osimertinib (3) · AZD 6244 (3) · Docetaxel (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 3 most studied

New when their studies opened, with capivasertib beside them; studies of each.

  • 1AZD9833
  • 1AMXT-1501 dicaprate
  • 1IPN-60090
Reaching primary completion within a year · 6, 3 in phase 3

Studies that test capivasertib, phase 3 first.

Studies

Open first, then newest update. How each study uses capivasertib has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 55

See all 55 studies that test capivasertib →

Behind its US label · 1 — the studies the FDA label of TRUQAP describes

From the Clinical Studies section of TRUQAP (2026-06), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 12 — no other medicine in its arm
Tested with established drugs · 18 — they are given beside it
Tested in a combination · 25 — another drug in the study is under test too

Showing 20 of 25. See all 25 →

Beside a new treatment under test · 5 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with capivasertib: AZD9833 1 · AMXT-1501 dicaprate 1 · IPN-60090 1

Beside supportive care · 2 — a supportive treatment or test is studied
One option of several · 2 — a test or a strategy chooses among drugs
As the comparator · 2 — what is tested is compared with capivasertib
Observed · 2 — patients on it are followed, or it is given outside a trial

Codes

What other systems call capivasertib · ClinicalTrials.gg INT006151

  • MeSH (NLM) C575618capivasertibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) WFR23M21IECAPIVASERTIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q27074756capivasertibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C102564CapivasertibOne source FDA
  • DrugBank DB12218One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion